K. Lin

发表

Cancer Therapy: Preclinical DownregulationofHumanEndogenousRetrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth

Donghui Li, Yue Lu, Jianjun Shen, 2019 .

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

B. Monk, M. Morgan, D. Provencher, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10

A. Oza, Y. Drew, R. Glasspool, 2022, British Journal of Cancer.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Anne Floquet, Andrew R Allen, James X. Sun, 2017, The Lancet. Oncology.

Title Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility Permalink

D. Albertson, A. Balmain, J. Pérez-Losada, 2011 .

Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility

Allan Balmain, D. Albertson, A. Balmain, 2011, Genome Biology.

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

U. Reineke, J. Ungewiss, T. Harding, 2022, European Journal of Nuclear Medicine and Molecular Imaging.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

James X. Sun, A. Tinker, D. Bowtell, 2017, Cancer discovery.

Kondrashova, O. et al. (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer

Swisher, James X. Sun, A. Tinker, 2017 .

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

A. Tinker, A. Oza, D. Provencher, 2021, Nature Communications.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, S. Lade, N. Traficante, 2018, Nature Communications.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.

K. Hunt, S. Ambs, S. Glynn, 2012, Journal of the National Cancer Institute.

SPOP mutation confers sensitivity to AR-targeted therapy in prostate cancer by reshaping the androgen-driven chromatin landscape

O. Elemento, A. Sboner, E. Davicioni, 2021, bioRxiv.

Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity

O. Elemento, A. Sboner, E. Davicioni, 2021, Cell reports.

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.

Jiaoti Huang, J. Qin, G. Palapattu, 2012, Cell stem cell.

Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC).

A. Tinker, A. Oza, J. Brenton, 2016 .

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

James X. Sun, A. Tinker, A. Oza, 2018, Cancer discovery.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

S. Fox, K. Byth, S. Lade, 2018, Nature Communications.

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.

A. Oza, J. Ledermann, E. Swisher, 2022, Gynecologic oncology.

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.

A. Tinker, A. Oza, D. Provencher, 2021, Gynecologic oncology.

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

A. Biankin, S. Domchek, R. McWilliams, 2018, JCO precision oncology.

Abstract 3650: Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

S. Orsulic, M. Raponi, T. Harding, 2017 .

Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

R. Yelensky, A. Tinker, A. Oza, 2015 .

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10

E. Swisher, I. McNeish, S. Goble, 2023, EBioMedicine.

Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

Christian A. Ross, Hu Li, C. Scott, 2021, NAR cancer.

Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

Christian A. Ross, Hu Li, C. Scott, 2020, bioRxiv.

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Juswinder Singh, W. Pao, T. van Dyke, 2013, Cancer discovery.

Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib.

A. Tinker, A. Oza, J. Ledermann, 2021, JAMA oncology.

Environmental Estrogens Differentially Engage the Histone Methyltransferase EZH2 to Increase Risk of Uterine Tumorigenesis

C. Walker, K. Kannan, J. Everitt, 2012, Molecular Cancer Research.

Signaling and Regulation Environmental Estrogens Differentially Engage the Histone Methyltransferase EZH 2 to Increase Risk of Uterine Tumorigenesis

C. Walker, K. Kannan, J. Everitt, 2012 .

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

B. Monk, A. Oza, F. Marmé, 2021, International Journal of Gynecological Cancer.

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Cesar M. Castro, James X. Sun, A. Tinker, 2017, Gynecologic oncology.

Cytotoxicity of Human Endogenous Retrovirus K–Specific T Cells toward Autologous Ovarian Cancer Cells

L. Ramondetta, D. Tang, K. Rycaj, 2014, Clinical Cancer Research.

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance

Sourav Bandyopadhyay, M. Raponi, Swati Kaushik, 2018, Cell reports.

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.

A. Oza, I. Bondarenko, N. Colombo, 2022, The Lancet. Oncology.

Characterization of patients (pts) with long-term responses to rucaparib in recurrent ovarian cancer (OC).

A. Tinker, A. Oza, D. Provencher, 2020 .

Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)

James X. Sun, A. Oza, J. Ledermann, 2018, Metabolic Changes in Ovarian Cancer.

Downregulation of Human Endogenous Retrovirus Type K (HERV-K) Viral env RNA in Pancreatic Cancer Cells Decreases Cell Proliferation and Tumor Growth

Donghui Li, Yue Lu, Jianjun Shen, 2017, Clinical Cancer Research.

Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas

Il-Jin Kim, Kuang-Yu Jen, Brian Jo, 2013, Nature Communications.

Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer

Xin Chen, Yue Lu, Can Liu, 2016, Clinical Cancer Research.

BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

N. Traficante, A. deFazio, J. Bedő, 2023, medRxiv.

Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3

A. Oza, J. Ledermann, E. Swisher, 2020 .

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

G. Shapiro, T. Yap, R. Jeselsohn, 2022, JCO precision oncology.

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.

A. Biankin, S. Domchek, R. Wolff, 2016 .

Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model

S. Orsulic, M. Raponi, T. Harding, 2017 .

518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation

A. Oza, D. Cibula, K. Mclachlan, 2022, Annals of Oncology.

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.

Cesar M. Castro, A. Tinker, A. Oza, 2021, Gynecologic oncology.

BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1

A. Tinker, E. Swisher, I. McNeish, 2017 .

Abstract C189: CO-1686, an orally available, mutant-selective inhibitor of the epidermal growth factor receptor (EGFR), causes tumor shrinkage in non-small cell lung cancer (NSCLC) with T790M mutations.

Juswinder Singh, M. Nacht, M. Raponi, 2011 .

Abstract CT158: ATHENA (GOG-3020/ENGOT-ov45): a randomized, double-blind, placebo-controlled, Phase III study of rucaparib + nivolumab following front-line platinum-based chemotherapy in ovarian cancer

B. Monk, A. Oza, F. Marmé, 2019, Clinical Trials.

Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high-grade serous carcinoma on the ARIEL2 trial.

A. Oza, J. Brenton, E. Swisher, 2016 .

Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer

Xin Chen, Yue Lu, Can Liu, 2016, Clinical Cancer Research.

Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.

K. Hunt, S. Ambs, S. Glynn, 2012, Journal of the National Cancer Institute.

Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC).

James X. Sun, G. Frampton, J. Suh, 2017 .